<DOC>
	<DOCNO>NCT00989287</DOCNO>
	<brief_summary>The objective study evaluate immunogenicity safety GSK Biologicals ' investigational vaccine GSK2340272A adult age 18 60 year .</brief_summary>
	<brief_title>Immunogenicity Safety Study Investigational Influenza ( H1N1 Influenza Virus ) Vaccine Adults</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol amendment 1 , October 2009 . The impacted section outcome measure section .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female age 18 60 year time first vaccination . Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Satisfactory baseline medical assessment history physical examination . Stable health status define absence health event satisfy definition SAE , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within one month prior enrolment . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Potential subject followup phase prior investigational study may enrol investigator 's judgment effect safety , reactogenicity , immunogenicity endpoint study , violate protocol requirement prior trial . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence axillary temperature &gt; = 37.5°C , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within past three year . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Clinically virologically confirm influenza infection within six month precede study start . Chronic administration immunosuppressant immune modify drug within six month study enrolment plan administration study period . For corticosteroid , mean dose equivalent 20 mg/day prednisone equivalent person &gt; two week . Inhaled topical steroid allow . Receipt immunoglobulins and/or blood product within three month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome . Administration vaccine within 30 day vaccination . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340272A</keyword>
	<keyword>influenza infection</keyword>
</DOC>